Authors

EYLEA’s unique MoA: What is the rationale for the higher molar dose?

A-memia? Anecdotal evidence in the era of memes

Ian C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter 2024 editorial.

Advancements in ocular drug delivery

Options empower patients and providers to decrease treatment burden

EYLEA 8mg in focus: Key learnings from the pivotal trials

Real World insights with EYLEA 8mg

Propelling R&D for Novel Retinal Therapies Through Innovative Clinical Trial Design

A field guide to optic disc drusen

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.

Foundation Fighting Blindness releases 4-year RUSH2A data to public

RUSH2A is an ongoing natural history study for patients with mutations in the USH2A gene causing Usher syndrome type 2A or nonsyndromic retinitis pigmentosa (RP).

Regeneron receives another CRL for its Eylea 8 mg

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

Boehringer Ingelheim launches two Phase 2 clinical trials for its geographic atrophy treatment candidates

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests.

Wet AMD therapeutics: Technologies raising the ceiling for functional visual outcomes

Neovascular macular degeneration is multifactorial, which requires future agents to target multiple pathways.

Corza Medical announces launch of the SensorTek ROP Kit

According to the company, this is the first and only single-use kit on the market that includes the diagnostic lens.Corza Medical has announced the commercial launch of the SensorTek ROP Kit, a single-use kit that includes a diagnostic lens for performing retinopathy of prematurity (ROP) examinations. According to the company, this is the first and only single-use kit on the market that includes the diagnostic lens. The kit is engineered specifically for the “unique demands of neonatal ophthalmology” and “streamlines workflow and helps reduce the risk of cross-contamination to help ensure every exam is performed with sterile, high-quality instruments and a crystal-clear lens.” The SensorTek ROP kit includes: A 28D diagnostic lens optimized for infant retinal visualization (K30-2415) Blink Single-Use stainless steel pediatric speculum (31-3103) Blink Single-Use ergonomic Epley scleral depressor (51-0004)

OSN New York Retina 2024: Understanding how next-generation anti-VEGFs perform in real-world settings compared to trials

Ferhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into their performance and safety beyond clinical trials.

EyePoint receives second consecutive positive recommendation from DSMC

EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for improved patient outcomes.